PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resistance by cellular compartment, obscuring the coordinated nature of tumor adaptation. Here, we introduce immune-pressure redistribution as a treatment-oriented frame...
Integrated analysis of public transcriptomic datasets identify an RBCK1-HLTF-JAK2/STAT3 regulatory axis that promotes cisplatin resistance in bladder cancer cells, and xenograft validation further supports the role of RBCK1 depletion in enhancing cisplatin response in vivo.
Xin Yang, Ze-Xian Ding, Peng-Wang Ya et al.· Pathology, Research and Prac...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.